Trials / Unknown
UnknownNCT02246465
A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars
An Open-Label, Multi-Center, Prospective, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery for Hypertrophic Scars in Healthy Adults
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- RXi Pharmaceuticals, Corp. · Industry
- Sex
- All
- Age
- 21 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a pre-existing hypertrophic scar.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RXI-109 |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2017-12-01
- Completion
- 2018-03-01
- First posted
- 2014-09-22
- Last updated
- 2018-02-23
Locations
6 sites across 2 countries: United States, Honduras
Source: ClinicalTrials.gov record NCT02246465. Inclusion in this directory is not an endorsement.